Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects up to 25% of children and 10% of adults. The skin of patients with moderate to severe AD is characterized by significant barrier disruption and T helper 2 (Th2)-driven inflammation, which are thought to play a significant role in the pathogenesis of AD. Current management of AD is aimed at suppressing the inflammatory response and restoring the barrier function of the skin, reducing exacerbations, and preventing secondary skin infections. Combinations of treatment strategies are used to alleviate the symptoms of the disease; however, resolution is often temporary, and long-term usage of some of the medications for AD can be associated with significant side effects. Antibody therapies previously approved for other inflammatory diseases have been evaluated in patients with AD. Unfortunately, they have often failed to result in significant clinical improvement. Monoclonal antibodies and novel small molecules currently in development may provide more consistent benefit to patients with AD by specifically targeting the immune and molecular pathways important for the pathogenesis of AD. Here we review the state-of-the-art therapeutics targeting the Th2 axis in AD.

Keywords:
Atopic dermatitis, Atopic eczema, Immunoglobulin E, Monoclonal antibodies, Allergy, Hypersensitivity, Pruritus
1.
Weidinger S, Novak N: Atopic dermatitis. Lancet 2015;387:1109-1122.
2.
Silverberg JI, Silverberg NB: Atopic dermatitis: update on pathogenesis and comorbidities. Curr Dermatol Rep 2012;1:168-178.
3.
Silverberg JI, Hanifin JM: Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 2013;132:1132-1138.
4.
Shaw TE, Currie GP, Koudelka CW, Simpson EL: Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol 2011;131:67-73.
5.
Hanifin JM, Reed ML: A population-based survey of eczema prevalence in the United States. Dermatitis 2007;18:82-91.
6.
Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483-1494.
7.
Bannister MJ, Freeman S: Adult-onset atopic dermatitis. Australas J Dermatol 2000;41:225-228.
8.
Ozkaya E: Adult-onset atopic dermatitis. J Am Acad Dermatol 2005;52:579-582.
9.
Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ: Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17-27.
10.
Tsakok T, Marrs T, Mohsin M, Baron S, Du Toit G, Till S, Carsten F: Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol 2016;137:1071-1078.
11.
Abuabara K, Margolis DJ: Do children really outgrow their eczema, or is there more than one eczema? J Allergy Clin Immunol 2013;132:1139-1140.
12.
Martinez FD: New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol 2011;128:939--945.
13.
Kattan J: The prevalence and natural history of food allergy. Curr Allergy Asthma Rep 2016;16:47.
14.
Lee E, Lee SH, Kwon J-W, Kim Y, Cho HJ, Yang SI, Jung YH, Kim HY, Seo JH, Kim BJ, Kim HB, Lee SY, Kwon HJ, Hong SJ: Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy 2016;71:692-700.
15.
Loo EX, Shek LP, Goh A, Teoh OH, Chan YH, Soh SE, Saw SM, Kwek K, Gluckman PD, Godfrey KM, Chong YS, Lee BW, Van Bever HP: Atopic dermatitis in early life: evidence for at least three phenotypes? Results from the GUSTO Study. Int Arch Allergy Immunol 2015;166:273-279.
16.
van der Hulst AE, Klip H, Brand PLP: Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol 2007;120:565-569.
17.
von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindström CB, Svensson Å: Eczema in early childhood is strongly associated with the development of asthma and rhinitis in a prospective cohort. BMC Dermatol 2012;12:11.
18.
Weidinger S, Willis-Owen SAG, Kamatani Y, Baurecht H, Morar N, Liang L, et al: A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis. Hum Mol Genet 2013;22:4841-4856.
19.
Zheng T, Yu J, Oh MH, Zhu Z: The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res 2011;3:67-73.
20.
Fishbein AB, Vitaterna O, Haugh IM, Bavishi AA, Zee PC, Turek FW, Sheldon SH, Silverberg JI, Paller AS: Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol 2015;136:1170-1177.
21.
Blome C, Radtke MA, Eissing L, Augustin M: Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am J Clin Dermatol 2016;17:163-169.
22.
Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Mastey V: Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016;74:491-498.
23.
Mansouri Y, Guttman-Yassky E: Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 2015;4:858-873.
24.
Howell MD, Parker ML, Mustelin T, Ranade K: Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015;70:887-896.
25.
Malajian D, Guttman-Yassky E: New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2015;73:311-318.
26.
Irvine AD, McLean WHI, Leung DYM: Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011;365:1315-1327.
27.
Thyssen JP, Kezic S: Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 2014;134:792-799.
28.
Linneberg A, Fenger R V, Husemoen LL, Thuesen BH, Skaaby T, Gonzalez-Quintela A, Vidal C, Carlsen BC, Johansen JD, Menné T, Stender S, Melgaard M, Szecsi PB, Berg ND, Thyssen JP: Association between loss-of-function mutations in the filaggrin gene and self-reported food allergy and alcohol sensitivity. Int Arch Allergy Immunol 2013;161:234-242.
29.
Cabanillas B, Novak N: Atopic dermatitis and filaggrin. Curr Opin Immunol 2016;17:42: 1-8.
30.
Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, Nakashima C, Nakajima S, Watanabe T, Miyachi Y, Narumiya S, Kabashima K, et al: Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol 2014;133:139-146.
31.
Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, Dainichi T, Honda T, Otsuka A, Kimoto Y, Yamamoto Y, Tanimoto A, Matsushita M, Miyachi Y, Kabashima K: The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 2015;136:667-677.
32.
Ming M, Zhao B, Shea CR, Shah P, Qiang L, White SR, Sims DM, He YY: Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 2015;135:936-945.
33.
Lio PA, Lee M, LeBovidge J, Timmons KG, Schneider L: Clinical management of atopic dermatitis: practical highlights and updates from the Atopic Dermatitis Practice Parameter 2012. J Allergy Clin Immunol Pract 2014;2:361-369.
34.
Di Filippo P, Scaparrotta A, Rapino D, Cingolani A, Attanasi M, Petrosino MI, Chuang K, Di Pillo S, Chiarelli F: Vitamin D supplementation modulates the immune system and improves atopic dermatitis in children. Int Arch Allergy Immunol 2015;166:91-96.
35.
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, Gieler U, Lipozencic J, Luger T, Oranje AP, Schäfer T, Schwennesen T, Seidenari S, Simon D, Ständer S, Stingl G, Szalai S, Szepietowski JC, Taïeb A, Werfel T, Wollenberg A, Darsow U; European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network: Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-1060.
36.
Chi CC, Kirtschig G, Aberer W, Gabbud JP, Lipozenčić J, Kárpáti S, Haustein UF, Zuberbier T, Wojnarowska F: Evidence-based (S3) guideline on topical corticosteroids in pregnancy. Br J Dermatol 2011;165:943-952.
37.
Boguniewicz M: Atopic dermatitis: the updated practice parameter and beyond. Allergy Asthma Proc 2014;35:429-434.
38.
Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, Fölster-Holst R, Gelmetti C, Hernández-Martin A, Middelkamp-Hup MA, Oranje AP, Logan K, Perkin M, Patrizi A, Rovatti G, Schofield O, Spuls P, Svensson Å, Vestergaard C, Wahlgren CF, Schmitt J, Flohr C; European Dermato-Epidemiology Network (EDEN): The European Treatment of Severe Atopic Eczema in Children Taskforce (TREAT) survey. Br J Dermatol 2013;169:901-909.
39.
Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
40.
Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, Mitsui H, Cardinale I, de Guzman Strong C, Krueger JG, Guttman-Yassky E: Progressive activation of T(h)2/T(h)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-1354.
41.
Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-3269.
42.
Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, Lee JH, Lee ES, Yang JM: Differential in vivo cytokine mRNA expression in lesional skin of intrinsic versus extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin Exp Allergy 2003;33:1717-1724.
43.
Teraki Y, Sakurai A, Izaki S: IL-13/IL-22-coproducing T cells, a novel subset, are increased in atopic dermatitis. J Allergy Clin Immunol 2013;132:971-974.
44.
Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Krueger JG, Guttman-Yassky E: Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 2015;136:104-115.
45.
Chan LS, Robinson N, Xu L: Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:977-983.
46.
Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z: Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 2008;129:742-751.
47.
Lee GR, Flavell RA: Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma. Int Immunol 2004;16:1155-1160.
48.
Sehra S, Yao Y, Howell MD, Nguyen ET, Kansas GS, Leung DY, Travers JB, Kaplan MH: IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 2010;184:3186-3190.
49.
Howell MD, Kim BE, Gao P, Grant A V, Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007;120:150-155.
50.
Kim BE, Leung DYM, Boguniewicz M, Howell MD: Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:332-337.
51.
Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, Hansen KC, Leung DY: Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 2008;128:2248-2258.
52.
De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Novak N, Weidinger S, Beaty TH, Leung DY, Barnes KC, Beck LA: Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011;127:773-786.
53.
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160.
54.
Albanesi C, Fairchild HR, Madonna S, Scarponi C, De Pità O, Leung DY, Howell MD: IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007;179:984-992.
55.
Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, Pavicic T, Boguniewicz M, Leung DY: Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006;117:836-841.
56.
Brauweiler AM, Goleva E, Leung DY: Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 2014;134:2114-2121.
57.
Burmeister Getz E, Fisher DM, Fuller R: Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009;49:1025-1036.
58.
Antoniu SA: Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010;11:1286-1294.
59.
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-139.
60.
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M: Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2015;387:40-52.
61.
Simon D, Braathen LR, Simon HU: Eosinophils and atopic dermatitis. Allergy 2004;59:561-570.
62.
Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP: Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012;42:712-737.
63.
Liu FT, Goodarzi H, Chen HY: IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol 2011;41:298-310.
64.
Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS: Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999;103:1103-1111.
65.
Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693-696.
66.
Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, Plötz S, Kapp A, Knol EF, Bruijnzeel-Koomen CA, Ring J, de Bruin-Weller MS: No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 2006;141:290-294.
67.
Comeau MR, Ziegler SF: The influence of TSLP on the allergic response. Mucosal Immunol 2010;3:138-147.
68.
Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt Rd R, Bazan F, Kastelein RA, Liu YJ: Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-680.
69.
Wang Y, Liu Y: Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses. Clin Exp Allergy 2009;39:798-806.
70.
Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, Comeau MR, Campbell DJ, Ziegler SF: Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005;202:541-549.
71.
He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS: TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci USA 2008;105:11875-11880.
72.
Jessup HK, Brewer AW, Omori M, Rickel EA, Budelsky AL, Yoon BR, Ziegler SF, Comeau MR: Intradermal administration of thymic stromal lymphopoietin induces a T cell and eosinophil-dependent systemic Th2 inflammatory response. J Immunol 2008;181:4311-4319.
73.
Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, Pellegrino M, Estandian DM, Bautista DM: The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013;155:285-295.
74.
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD: Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2015;15:35-50.
75.
Rochman Y, Kashyap M, Robinson GW, Sakamoto K, Gomez-Rodriguez J, Wagner KU, Leonard WJ: Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signalling. Proc Natl Acad Sci USA 2010;107:19455-19460.
76.
Levy LL, Urban J, King BA: Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 2015;73:395-399.
77.
Kostenis E, Ulven T: Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006;12:148-158.
78.
Spik I, Brénuchon C, Angéli V, Staumont D, Fleury S, Capron M, Trottein F, Dombrowicz D: Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol 2005;174:3703-3708.
79.
Chevalier E, Stock J, Fisher T, Dupont M, Fric M, Fargeau H, Leport M, Soler S, Fabien S, Pruniaux MP, Fink M, Bertrand CP, McNeish J, Li B: Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 2005;175:2056-2060.
80.
Satoh T, Moroi R, Aritake K, Urade Y, Kanai Y, Sumi K, Yokozeki H, Hirai H, Nagata K, Hara T, Utsuyama M, Hirokawa K, Sugamura K, Nishioka K, Nakamura M: Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 2006;177:2621-2629.
81.
Oiwa M, Satoh T, Watanabe M, Niwa H, Hirai H, Nakamura M, Yokozeki H: CRTH2-dependent, STAT6-independent induction of cedar pollen dermatitis. Clin Exp Allergy 2008;38:1357-1366.
82.
Boehme SA, Chen EP, Franz-Bacon K, Sásik R, Sprague LJ, Ly TW, Hardiman G, Bacon KB: Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol 2009;21:1-17.
83.
Boehme SA, Franz-Bacon K, Chen EP, Sásik R, Sprague LJ, Ly TW, Hardiman G, Bacon KB: A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol 2009:21:81-93.
84.
Hijnen D, Nijhuis E, Bruin-Weller M, Holstege F, Koerkamp MG, Kok I, Bruijnzeel-Koomen C, Knol E: Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4+ T cells of patients with atopic dermatitis. J Invest Dermatol 2005;125:1149-1155.
85.
Iwasaki M, Nagata K, Takano S, Takahashi K, Ishii N, Ikezawa Z: Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J Invest Dermatol 2002;119:609-616.
86.
Novak N, Bieber T: Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252-262.
87.
Oettgen HC, Geha RS: IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999;104:829-835.
88.
Poulsen LK, Hummelshoj L: Triggers of IgE class switching and allergy development. Ann Med 2007;39:440-456.
89.
Denby KS, Beck LA: Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 2012;12:421-426.
90.
Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-340.
91.
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013;162:89-93.
92.
Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB: Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29:530-537.
93.
Park SY, Choi MR, Na JI, Youn SW, Park KC, Huh CH: Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22:349-352.
94.
Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, Andres C, Schnopp C, Ring J, Hein R, Ollert M, Mempel M: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-1225.
95.
Heil PM, Maurer D, Klein B, Hultsch T, Stingl G: Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990-998.
96.
Hotze M, Baurecht H, Rodríguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R, Adamski J, Illig T, Ring J, Weidinger S: Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014;69:132-135.
97.
Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ: Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014;44:1371-1385.
98.
Novartis Clinical Trial No. CQGE031X2201. http://www.novctrd.com (accessed March 15, 2016).
99.
Ando T, Hashiro M, Noda K, Adachi J, Hosoya R, Kamide R, Ishikawa T, Komaki G: Development and validation of the psychosomatic scale for atopic dermatitis in adults. J Dermatol 2006;33:439-450.
100.
Kiebert G, Sorensen S V., Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D: Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002;41:151-158.
101.
Sheldon E, Schwickart M, Li J, Kim K, Crouch S, Parveen S, Kell C, Birrell C: Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study. Adv Ther 2016;33:225-251.
102.
Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Sutherland ER, Mastey V: Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 2016;75:506-515.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.